Photocure ASA is a Norwegian specialty pharmaceutical company based in Oslo, focused on developing and commercializing pharmaceuticals and medical devices using proprietary photodynamic technology. Founded in 1993, the company aims to enhance bladder cancer diagnosis and management, positioning itself as a leader in this field with a robust intellectual property platform.

The flagship product, Hexvix (Cysview in the US), is a pharmaceutical agent that improves the detection of bladder cancer during blue light cystoscopy. Photocure is also advancing its pipeline with Cevira, a photodynamic drug-device combination in Phase II trials for treating HPV infections and precancerous cervical lesions. The company serves healthcare providers specializing in urology and oncology, with a strong presence in Europe and North America, and emphasizes collaboration with medical professionals and research institutions to further its mission.